Privately held Indian company, Biological E is investing $234 million in their three facilities in the Genome Valley of Hyderabad, India. The new infusion of funds will enhance the production capacity by five billion doses, increasing the cumulative capacity to about 14 billion doses per year. The company claims that this will make it the highest manufacturing capacity for any region in the world. Earlier this year, Gunjan Bagla, India expert and CEO of Amritt Inc visited and toured Biological E.
This investment will go toward enhancing the manufacture of vaccines including its own Corbevax, J&J’s Measles-Rubella, Pneumococcal Conjugate, Typhoid, Tetanus Toxide Ampoules, IPV vaccine, and Pertussis vaccine, biological APIs and formulations, specialty generic injectables and R&D.
The company secured funding of $50 million from the U.S. International Development Finance Corporation to expand its capacity to produce Covid-19 vaccines.
Biological E has four strategic business units in the state: Branded Formulations, Specialty Generic Injectables, Synthetic Biology, Vaccines and Biologics. The company has six manufacturing facilities where more than 5,000 people are employed.
